| Ytd | -70.18% | |
| 1y | -70.18% |
| Open | 1.75 | Prev Close | 1.73 | Low | 1.74 | High | 1.84 | Mkt Cap | 146.30M |
| Vol | 682.37K | Avg Vol | 922.67K | EPS | -0.27 | P/E | -6.53 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-18 | 50-d Avg | 2.29 | 200-d Avg | 3.53 | 1yr Est | 0.00 |
Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a
Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a O
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe
US stocks rise with the Dow gaining 250 points. Health care shares jump while energy stocks fall. BJ
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe
Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrade